The Trump administration has announced that it is offering a large sum of money to a German biopharmaceutical firm to move its research on a coronavirus vaccine to the US.
The German daily reported that the White House’s attempt to relocate CareVac, a research company based in Tuebingen, was aimed at securing exclusive access to the drug when it was ready. It quoted a German government official saying the offer was to develop the vaccine “only for the United States”.
The move prompted the German government to offer its own financial incentives to keep the company in the country.
A German Health Ministry later confirmed the report.
CureVac is one of a number of companies currently working on a vaccine for the coronavirus. Last week it said it hopes to have an experimental vaccine ready by June or July, and would push for human testing soon after.
Daniel Menichella ,CureVac’s chief executive met with president Donald Trump and vice president Mike Pence, earlier this month, at the White House to discuss the company’s work on a vaccine.
Menichella said he was “very confident that we will be able to develop a potent vaccine candidate within a few months.”